Showing results (121-130 of 141) with videos related to
Sort By:
Pageof 15
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2007
Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trialsR Conforti, T Boulet, G Tomasic, et al.European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 7, 2004
Quality of life after sentinel lymph node biopsy in early breast cancerG Dubernard, L Sideris, S Delaloge, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 26, 2008
Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacyM Zoubir, M C Mathieu, C Mazouni, et al.Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|September 20, 2000
[Alternating chemotherapy and hyperfractionated accelerated radiotherapy in non-metastatic inflammatory breast cancer]A Hasbini, C Le Péchoux, B Roche, et al.Oncogene|December 5, 2000
Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: prevalence of alterations in inflammatory breast cancersJ C Ahomadegbe, S Tourpin, M Kaghad, et al.British Journal of Cancer|August 1, 1996
A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitorI Smith, A Jones, M Spielmann, et al.Bulletin Du Cancer|February 1, 1997
[Angiosarcoma of the breast. Apropos of 8 cases and review of the literature]J L Molitor, A Llombart, J M Guinebretière, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2012
Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancerF Andre, R Conforti, C B Moeder, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 21, 1999
Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma?A Le Cesne, G Vassal, F Farace, et al.Seminars in Oncology|February 1, 1997
Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experienceG Catimel, M Spielmann, V Dieras, et al.Pageof 15